Novo Nordisk Cuts Wegovy and Ozempic Prices 50% Starting January 2027

Medically reviewed by a licensed healthcare professional. Last updated March 2026.

What Novo Nordisk Announced

In early 2026, Novo Nordisk confirmed plans to reduce the wholesale acquisition cost (list price) of its GLP-1 medications by approximately 50%. The change applies to both Wegovy (semaglutide for weight management) and Ozempic (semaglutide for type 2 diabetes) and is scheduled to take effect in January 2027.

Under the new pricing, Wegovy's list price will drop from roughly $1,349 per month to approximately $675 per month. Ozempic will see a comparable percentage reduction, bringing its list price more in line with what many patients and insurers have been demanding.

This is one of the largest voluntary price reductions in the history of branded prescription medications.

Why This Is Happening

The price cut did not happen in a vacuum. Several powerful forces converged to push Novo Nordisk toward this decision.

Competition From Eli Lilly

Eli Lilly's tirzepatide (sold as Zepbound for weight management and Mounjaro for diabetes) has captured significant market share since its launch. In clinical trials, tirzepatide demonstrated weight loss results that matched or exceeded semaglutide, and Lilly has been aggressive with its pricing and patient access programs.

Lilly also launched LillyDirect, a platform that sells Zepbound directly to patients at reduced prices, bypassing traditional pharmacy benefit managers. This move put direct pricing pressure on Novo Nordisk.

When your competitor offers a product that performs at least as well and is actively undercutting you on price, standing pat is not an option.

The Compounding Pharmacy Factor

Perhaps the most disruptive force has been compounding pharmacies. During the FDA-designated shortage of semaglutide and tirzepatide, compounding pharmacies were legally permitted to produce copies of these medications. Many patients switched to compounded semaglutide at prices of $200 to $500 per month, a fraction of the brand-name cost.

Even as shortage designations have been revisited, the compounding market has shown patients that effective GLP-1 treatment does not have to cost over $1,000 per month. That awareness is hard to undo.

Political Pressure

GLP-1 drug pricing has become a political issue. Lawmakers on both sides of the aisle have questioned why medications that cost a fraction of their U.S. price in other countries remain so expensive for American patients. Congressional hearings, executive orders on drug pricing, and the expansion of Medicare negotiation authority have all contributed to an environment where maintaining high list prices carries significant reputational and regulatory risk.

Novo Nordisk executives have faced direct questioning about pricing in public forums, and the company has been cited in multiple policy proposals targeting pharmaceutical pricing reform.

The Broader Market Shift

The GLP-1 market is no longer a two-player game. Several new medications are in late-stage clinical trials, including oral formulations and next-generation injectables from multiple pharmaceutical companies. Novo Nordisk is positioning itself to remain competitive as the market expands.

What This Means for Patients

If You Pay Out of Pocket

The most direct impact will be for cash-pay patients. A reduction from $1,349 to $675 per month translates to savings of approximately $8,088 per year. For many patients who have been unable to afford brand-name Wegovy, this brings the medication within reach, though it is still more expensive than many compounded alternatives.

For a full comparison of payment options, visit our cost guide.

If You Have Insurance

The list price reduction should eventually translate to lower costs throughout the insurance system. Here is how:

• Lower copays and coinsurance: If your plan bases your cost on a percentage of the list price, your out-of-pocket amount should decrease proportionally.
• Easier prior authorization: Insurers are more likely to approve coverage for medications with lower list prices because they cost the plan less.
• Formulary inclusion: Plans that previously excluded Wegovy or Ozempic due to cost may reconsider adding them to their formularies.
• Reduced deductible impact: If you are on a high-deductible plan, a lower list price means less spent before your insurance kicks in.

However, these changes will not happen overnight. Insurance formularies and pricing structures typically update annually or semi-annually, so the full impact may not be felt until mid-to-late 2027.

Check our insurance guide for current coverage details.

If You Are on Compounded Semaglutide

Patients currently using compounded semaglutide may wonder whether to switch back to brand-name Wegovy once the price drops. At $675 per month, brand-name Wegovy will still be more expensive than most compounded options ($200 to $500 per month), but the gap narrows significantly.

Factors to consider when deciding:

• Brand-name medications go through the full FDA approval process and are subject to more rigorous quality controls than compounded versions.
• Your insurance is much more likely to cover brand-name Wegovy than compounded semaglutide.
• If you are doing well on compounded semaglutide, there is no medical reason to switch simply because of a price change.

What You Should Do Right Now

Do Not Wait to Start Treatment

If you qualify for GLP-1 therapy and have been considering it, do not wait nine months for the price cut. Obesity and type 2 diabetes are progressive conditions, and delaying treatment has real health consequences. Manufacturer savings programs, insurance coverage, and compounded alternatives are available today.

Check Your Current Coverage

Contact your insurance provider and ask whether the price reduction will affect your plan's coverage or copay structure. While most changes will not take effect until 2027, some plans may begin making adjustments earlier.

Explore All Your Options Now

Use our telehealth provider directory to compare current pricing from multiple providers. Many patients find that between savings programs, telehealth bundles, and compounded options, affordable treatment is already available.

Talk to Your Provider

If cost has been a barrier to starting or continuing GLP-1 treatment, bring this up at your next appointment. Providers can often help with manufacturer copay cards, alternative medications, or connecting you with more affordable dispensing options.

The Bigger Picture

Novo Nordisk's price cut is a significant moment for the GLP-1 market, but it is part of a larger trend toward greater affordability and access. The combination of competition, compounding, political will, and patient advocacy is reshaping how these medications are priced and distributed.

For patients, the trajectory is encouraging. Prices are moving in the right direction, insurance coverage is expanding, and the number of available treatment options continues to grow. The question is no longer whether GLP-1 medications will become more affordable, but how quickly.

We will continue tracking pricing changes and coverage updates. Bookmark our cost guide for the latest information.

Sources

1. Novo Nordisk. "Novo Nordisk Announces U.S. List Price Reductions for Wegovy and Ozempic." Press Release. 2026.
2. Eli Lilly. "LillyDirect: Direct-to-Patient Pricing for Zepbound." LillyDirect.com. 2025.
3. U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." FDA.gov. 2025.
4. Congressional Budget Office. "Prescription Drug Pricing and the Medicare Negotiation Program." CBO.gov. 2025.
5. Novo Nordisk Annual Report 2025. "Financial Statements and Market Analysis." NovoNordisk.com. 2026.
6. IQVIA. "GLP-1 Market Dynamics and Competitive Landscape Report." 2026.